-
Recent Posts
- A Renaissance in Chronic Kidney Disease Treatment Is Underway
- Akebia Therapeutics Announces Approval of Vadadustat in Japan for the Treatment of Anemia Due to Chronic Kidney Disease in Dialysis-Dependent and Non-Dialysis Dependent Adult Patients
- Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis
- A proposed clinical trial for COVID-19 pneumonia
- Dapagliflozin–saxagliptin ‘attractive’ options for patients with type 2 diabetes with chronic kidney disease
Recent Comments
Archives
- January 2021
- July 2020
- May 2020
- April 2020
- May 2019
- February 2019
- January 2019
- November 2018
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- December 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- November 2012
- October 2012
- May 2012
- December 2011
- May 2011
Categories
Meta
Monthly Archives: September 2017
Amgen and AbbVie reach a settlement on Humira biosimilar patent litigation
From Reuters (September 28, 2017) Amgen Inc has reached a settlement with AbbVie Inc that will delay the U.S. launch of Amgen’s cheaper biosimilar version of AbbVie’s cash cow, the blockbuster rheumatoid arthritis drug Humira, until Jan. 31, 2023, the … Continue reading
Posted in M Loghman-Adham, MD
Leave a comment